gemcitabine mylan [gemcitabine strides]
mylan s.a.s. - gemcitabinas - milteliai infuziniam tirpalui - 38 mg/ml - gemcitabine
irinotecan mylan [irinotecan strides]
mylan s.a.s. - irinotekano hidrochloridas trihidratas - koncentratas infuziniam tirpalui - 20 mg/ml - irinotecan
oxaliplatin mylan
mylan s.a.s. - oksaliplatina - milteliai infuziniam tirpalui - 5 mg/ml - oxaliplatin
vinorelbine mylan [vinorelbine strides]
mylan s.a.s. - vinorelbinas - koncentratas infuziniam tirpalui - 10 mg/ml - vinorelbine
doksorubicinas mylan [doksorubicinas agila]
mylan s.a.s. - doksorubicinas - milteliai infuzinio tirpalo koncentratui - 2 mg/ml - doxorubicin
pyridostigmine bromide mylan
mylan ireland limited - piridostigmino bromidas - pailginto atpalaidavimo tabletės - 180 mg - pyridostigmine
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - klopidogrelio hidrochloridas - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitromboziniai vaistai - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
influvac
mylan ire healthcare limited - Į a/victoria/2570/2019 (h1n1)pdm09 panašios padermės (a/victoria/2570/2019 ivr‐215)/Į a/cambodia/e0826360/2020 (h3n2) panašios padermės (a/cambodia/e0826360/2020 ivr‐224)/į b/washington/02/2019 panaši padermė (b/washington/02/2019, laukinis tipas) - injekcinė suspensija - 15 µg ha/15 µg ha/15 µg/dozėje - influenza, inactivated, split virus or surface antigen
kreon 20000 v [pancreas powder mylan]
viatris healthcare limited - kasos milteliai (lipazė/amilazė/proteazė) - skrandyje neirios kietosios kapsulės - 300 mg (20000 v/16000 v/1200 v); 20000 v/16000 v/1200 v - multienzymes (lipase, protease etc.)
kreon 35000 v [pancreas powder mylan]
viatris healthcare limited - kasos milteliai (lipazė/amilazė/proteazė) - skrandyje neirios kietosios kapsulės - 420 mg (35000 v/25200 v/1400 v); 35000 v/25200 v/1400 v - multienzymes (lipase, protease etc.)